The impact of anti-tumor necrosis factor alpha drugs on lipid profile of patients with rheumatoid arthritis or seronegative spondyloarthropathy
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20233890Keywords:
Lipid profile, Rheumatoid arthritis, Seronegative spondyloarthritisAbstract
Background: Inflammatory arthritis is associated with abnormal levels of lipoprotein. The cause is considered to be inflammation. Recently, the use of biologic drugs in the treatment of inflammatory arthritis, especially rheumatoid arthritis (RA) and seronegative spondyloarthropathy, has increased. There are different results of the effect of these drugs on fat profile. Evaluate the impact of anti-tumor necrosis factor (TNF) alpha drugs on lipid profile of patients with RA or seronegative spondyloarthritis.
Methods: In this cross-sectional descriptive study, 50 patients with rheumatoid arthritis or seronegative spondyloarthritis, who were candidates for TNF alpha treatment, were included in the study. After obtaining written consent, a checklist was completed for all patients including demographic information such as age, sex, height, weight, place of residence, level of education, type of disease, and lipid profile test results including total cholesterol, triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL) were recorded. Then the patients were treated and evaluated for fat profile after 3, 6, 9 months after receiving the relevant treatment regimen. The test results were recorded in checklists. After completing the study, the data were entered into the statistical package for the social sciences (SPSS) 24 software and analyzed.
Results: The mean age of patients was 46.38±14.33 years. 54% of patients were female. 54% of patients had rheumatoid arthritis. 62% of patients were treated with Sinora. The results of this study showed that serum triglyceride levels increased during the study period and this increase was statistically significant but the trend of changes in serum cholesterol, HDL and LDL levels was not statistically significant. However, serum LDL levels measured in the ninth month increased significantly compared to the initial measurement.
Conclusions: Results showed that there was a significant relationship between lipid profile changes and anti-TNF alpha consumption. Although decreased inflammation appears but other mechanisms may be involved in dyslipidemia.
References
Tanasan A, Eghbalian F, Sabzehei MK, Rastgoo Haghi A. The relationship between serum levels of troponin I and myocardial function in neonates under mechanical ventilation. Iranian J Pediatrics. 2020;30(1):1-5.
Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360-72.
Korani S, Korani M, Butler AE, Sahebkar A. Genetics and rheumatoid arthritis susceptibility in Iran. J Cellular Physiol. 2019;234(5):5578-87.
Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. The Lancet. 2017;389(10086):2338-48.
Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6(1):1-14.
Khan MA. Update on spondyloarthropathies. Ann Int Med. 2002;136(12):896-907.
Navallas M, Ares J, Beltrán B, Lisbona MP, Maymó J, Solano A. Sacroiliitis associated with axial spondyloarthropathy: new concepts and latest trends. Radiographics. 2013;33(4):933-56.
Jafri K, Taylor L, Nezamzadeh M, Baker JF, Mehta NN, Bartels C, et al. Management of hyperlipidemia among patients with rheumatoid arthritis in the primary care setting. BMC Musculoskeletal Disord. 2015;16(1):1-8.
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-19.
Tehlirian CV, Bathon JM. Rheumatoid arthritis. Primer on the rheumatic diseases: Springer. 2010;114-41.
Sen R, Goyal A, Bansal P, Hurley JA. Seronegative spondyloarthropathy. StatPearls Publishing. 2017.
Zagora SL, McCluskey P. Ocular manifestations of seronegative spondyloarthropathies. Curr Opin Ophthalmol. 2014;25(6):495-501.
Zochling J, Smith EU. Seronegative spondyloarthritis. Best Pract Res Clin Rheumatol. 2010;24(6):747-56.
Emad Y, Ragab Y, Bassyouni I, Moawayh O, Fawzy M, Saad A, et al. Enthesitis and related changes in the knees in seronegative spondyloarthropathies and skin psoriasis: magnetic resonance imaging case-control study. J Rheumatol. 2010;37(8):1709-17.
Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol. 2015;27(1):55-62.
Myasoedova E. Lipids and lipid changes with synthetic and biologic disease-modifying antirheumatic drug therapy in rheumatoid arthritis: implications for cardiovascular risk. Curr Opin Rheumatol. 2017;29(3):277-84.
Bergström U, Jovinge S, Persson J, Jacobsson LT, Turesson C. Effects of treatment with adalimumab on blood lipid levels and atherosclerosis in patients with rheumatoid arthritis. Curr Therap Res. 2018;89:1-6.
Hassan S, Feld J, Cohen S, Zisman D. The effect of biologic therapy on the lipid profile of rheumatoid arthritis (RA), psoriatic arthritis (PSA) and ankylosing spondylitis (AS) patients. Harefuah. 2017;156(7):446-50.
Ferraz Filho AC, dos Santos LP, Silva MB, Skare TL. Lipid profile and anti-TNF-α use. Rev Bras Reumatol. 2013;53(5):444-7.
França C, Mendes C, Ferreira C. Time collection and storage conditions of lipid profile. Brazi J Med Biol Res. 2018;51:6955.
Wang C-R, Tsai H-W. Anti-and non-tumor necrosis factor-α-targeted therapies effects on insulin resistance in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. World J Diabet. 2021;12(3):238.
Hassan S, Milman U, Feld J, Eder L, Lavi I, Cohen S, et al. Effects of anti-TNF-α treatment on lipid profile in rheumatic diseases: an analytical cohort study. Arth Res Therap. 2016;18(1):1-9.
Corrado A, Colia R, Rotondo C, Sanpaolo E, Cantatore FP. Changes in serum adipokines profile and insulin resistance in patients with rheumatoid arthritis treated with anti-TNF-α. Curr Med Res Opin. 2019;35(12):2197-205.
Cacciapaglia F, Anelli MG, Rinaldi A, Serafino L, Covelli M, Scioscia C, et al. Lipid Profile of Rheumatoid Arthritis Patients Treated with Anti‐Tumor Necrosis Factor‐Alpha Drugs Changes According to Disease Activity and Predicts Clinical Response. Drug Dev Res. 2014;75:S77-80.
Bergström U, Jovinge S, Persson J, Jacobsson LT, Turesson C. Effects of treatment with adalimumab on blood lipid levels and atherosclerosis in patients with rheumatoid arthritis. Curr Therap Res. 2018;89:1-6.
